315 results on '"Damiano, V."'
Search Results
2. Adolescent gender dysphoria management: position paper from the Italian Academy of Pediatrics, the Italian Society of Pediatrics, the Italian Society for Pediatric Endocrinology and Diabetes, the Italian Society of Adolescent Medicine and the Italian Society of Child and Adolescent Neuropsychiatry
Catalog
Books, media, physical & digital resources
3. Predictors of Asymptomatic Radiation-induced Abdominal Atherosclerosis
4. Letter: the response to somatostatin analogues in neuroendocrine tumours is influenced by the Ki67 score
5. Does morbid obesity influence perioperative outcomes after video-assisted thoracic surgery (VATS) lobectomy for non-small cell lung cancer? Analysis of the Italian VATS group registry
6. Combination of biological therapies in non-small cell lung cancer
7. Application of crude xylanase from Bacillus licheniformis 77-2 to the bleaching of eucalyptus Kraft pulp
8. Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer
9. In-vitro-, In-vivo- und Phase-I-Studien zu Oxaliplatin und Topotecan in Kombination bei humanen Karzinomen: 2461
10. Antitumor Activity and Potentiation of Chemotherapy in Human Cancer Cells by ZD-1839 (Iressa), an EGFR-Selective Tyrosine Kinase Inhibitor.
11. Core curriculum. Oncologia clinica
12. Ruolo dell'ecografia nella definizione della sindrome da Pseudotumor Cerebri
13. Letter: The response to somatostatin analogues in neuroendocrine tumours is influenced by the Ki67 score
14. SIMULTANEOUS VULVAR AND PARENCHIMAL BRAIN LANGERHANS CELL HISTIOCYTOSIS: ASSOCIATION OR COINCIDENCE?
15. Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in patients with non-small cell lung cancer <= 3 cm in size
16. P1.17-015 Long Acting Octreotide plus Prednisone in Advanced Thymic Epithelial Tumors: A Real Life Clinical Experience
17. P1.17-014 Platinum Rechallenge in Advanced Thymic Epithelial Tumors: Still an Option in the Age of Target Therapy? A Monocentric Experience
18. OC-0041: Predictors of asymptomatic radiation induced vascular damage to infradiaphragmatic vessels
19. SPHINGOSINE KINASE 1 (SPHK1) CONTRIBUTES TO RESISTANCE TO EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS IN COLORECTAL CANCER MODELS
20. INHIBITION OF CANCER CELL GROWTH AND INVASION BY TARGETING C-SRC IN BREAST CANCER MODELS RESISTANT TO ANTI-HER2 DRUGS
21. Adherence issues related to sublingual immunotherapy as perceived by allergists
22. Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells
23. VEGF Receptor 1 contributes to resistance to anti-EGFR drugs in human cancer cells
24. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumors sensitive and resistant to anti-EGFR drugs
25. Mechanisms of resistance to HER/erbB inhibitors
26. Inhibitors of HER/erB receptors: biological bases and clinical applications
27. Novel TLR9 agonist incuces EGFR inhibitions and synergistic antitumor activity with EGFR inhibitors
28. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumour activity with EGFR inhibitors
29. Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus : Results from the randomized, phase 2 LUNA study
30. Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: Results from the randomized, phase 2 LUNA study
31. Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer
32. cooperativ antitumor effect of multitarget kinase inhibitor zd6474 and ionizing radiation in glioblastoma
33. Antitumor activity ofZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiatesthe effects of radiation in a human non-small cell lung cancer xenograft model
34. Therapeutic integration of signal trasdution targeting agents an conventional anticancer treatments
35. COMBINED TARGETING OF EGFR AND MDM2 BY GEFITINIB AND ANTISENSE MDM2 COOPERATIVELY INHIBIT HORMONE-INDEPENDENT PROSTATE CANCER
36. Combined targeting of epidermal growthfactor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibithormone-independent prostate cancer
37. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity
38. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase
39. Combined targeted inhibition of Bcl-2, Bcl-xL, EGFR and Protein Kinase A Type I causes potent antitumor, apoptotic and antiangiogenic activity
40. Antitumor activity of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to EGF receptor-targeted drugs
41. Enhancement of antitumor activity of ionizing radiation by combinet treatnment with the selective EGFR- tyrosine kinase inhibitor ZD1839 (Iressa)
42. Inhibition of growth factors production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
43. Combined blockade of PKA and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis
44. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents
45. Oral antisense targeting protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis and growth factors production
46. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells
47. Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production
48. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
49. Somatostatin Analogs as mainteinance therapy in heavily pretreated thymic epithelial tumors
50. Effectiveness of somatostatin analogs plus prednisone in aggressive histotype and advanced stage of thymic epithelial tumors
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.